QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BIOA

QT47BioAge Labs, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
20.77
+0.78+3.90%
OverviewShort InterestFilings
BIOAQT47BioAge Labs, Inc.·NASDAQ
OverviewShort InterestFilings
20.77+3.90%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.40
Insider Own10.26%
Shs Outstand44.45M
Perf Week26.26%
Market Cap752.62MForward P/E-EPS next Y-1.88Insider Trans-0.33%Shs Float-Perf Month26.88%
Enterprise Value514.87MPEG0.55EPS next Q-0.65Inst Own-Short Float-Perf Quarter-1.28%
Income-79702056.00P/S72.96EPS this Y-6.53%Inst Trans-Short Ratio-Perf Half Y66.03%
Sales10.32MP/B2.24EPS next Y26.53%ROA-22.62%Short Interest-Perf YTD56.99%
Book/sh8.53P/C-EPS next 5Y-ROE-29.40%52W High24.00 -13.46%Perf Year377.47%
Cash/sh8.62P/FCF-EPS past 3/5Y-ROIC-26.51%52W Low4.07 410.32%Perf 3Y-
Dividend Est.-EV/EBITDA-5.77Sales past 3/5Y-Gross Margin99.39%Volatility5.78% 4.52%Perf 5Y-
Dividend TTM-EV/Sales49.91EPS Y/Y TTM-21.21%Oper. Margin-985.93%ATR (14)1.34Perf 10Y-
Dividend Ex-Date-Quick Ratio24.76Sales Y/Y TTM-Profit Margin-871.75%RSI (14)66.35Recom2.17
Dividend Gr. 3/5Y-Current Ratio24.76EPS Q/Q-44.44%SMA2020.16%Beta1.90Target Price42.20
Payout0.00%Debt/Eq0.01Sales Q/Q200.00%SMA5019.47%Rel Volume1.48Prev Close19.99
Employees62LT Debt/Eq0.01EarningsAug 05SMA20048.33%Avg Volume419.24KPrice20.77
IPO DateSep 26, 2024Option/ShortYes / YesEPS/Sales Surpr.18.70% 200.00%Net Debt/EBITDA2.67Volume619,575Change3.90%
Analyst Ratings
DateActionAnalystRatingTarget
May-27-26InitiatedRoth CapitalBuy$36
May-13-26InitiatedBTIGBuy$40
Mar-27-26InitiatedNeedhamBuy$50
Feb-18-26UpgradeJefferiesHold → Buy$7.00 → $62
Feb-04-26ReiteratedMorgan StanleyEqual Weight$12 → $23
Dec-08-25UpgradeMorgan StanleyUnderweight → Equal Weight$12
Oct-22-25UpgradeCitigroupNeutral → Buy
Mar-07-25ReiteratedMorgan Stanley$40 → $5.00
Dec-09-24DowngradeCitigroupBuy → Neutral
Dec-09-24DowngradeJefferiesBuy → Hold$42 → $7.00
Latest News
Jun-16-26
Jun-16-2608:01AM
BioAge Labs Doses First Participant Dosed In QUELL-CVBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue1090
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit1090
Selling, General and Administrative Excl. Other292819
Research and Development847459
Other Operating Expense-100
Operating Income-101-93-78
Interest Expense012
Unusual Expense
———
Non-Operating Income (Expense)-12-13-9
Net Income Before Taxes-90-81-71
Income Taxes
000
Consolidated Net Income-90-81-71
Net Income From Continuing Operations-90-81-71
Net Income-90-81-71
EPS (Recurring)-2.40-2.24-1.98
EPS (Basic, Before Extraordinaries)-2.40-2.24-1.98
EPS (Diluted)-2.40-2.24-1.98
EBITDA-89-80-69
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio87.2352.92—
Gross Margin100.00100.00—
Operating Margin-1,010.00-1,033.33—
Net Margin-900.00-900.00—
Shares Outstanding423636
Market Capitalization872476—
Operating Lease Expense
———
Insider Trading Volume
$22.52$19.73$16.93$14.14$11.34● Close Price0.00M1.21M2.43M3.64M4.85MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GOLDSTEIN DOV A MDChief Financial OfficerApr 23 '26Option Exercise4.387,08431,028155,833Apr 24 12:00 AM
RUBIN PAUL DChief Medical OfficerApr 01 '26Option Exercise5.0517,64089,1448,820Apr 03 12:00 AM
RUBIN PAUL DChief Medical OfficerApr 01 '26Sale17.818,820157,0840Apr 03 12:00 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Option Exercise4.7714,86670,9407,433Mar 03 12:00 AM
RUBIN PAUL DChief Medical OfficerMar 02 '26Sale20.307,433150,8900Mar 03 12:00 AM
GOLDSTEIN DOV A MDChief Financial OfficerMar 01 '26Option Exercise4.387,08431,028159,375Mar 03 12:00 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Option Exercise4.7714,86670,94010,870Feb 03 12:00 AM
RUBIN PAUL DChief Medical OfficerFeb 02 '26Sale18.757,433139,3690Feb 03 12:00 AM
GOLDSTEIN DOV A MDChief Financial OfficerFeb 01 '26Option Exercise4.387,08231,020162,917Feb 03 12:00 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 16 '26Option Exercise4.387,08431,028166,458Jan 21 12:00 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Option Exercise8.3954,000453,06092,587Jan 15 12:00 AM
GOLDSTEIN DOV A MDChief Financial OfficerJan 13 '26Sale19.7027,000531,82822,408Jan 15 12:00 AM
Fortney KristenChief Executive OfficerJan 13 '26Sale18.12233,1074,223,036976,949Jan 15 12:00 AM
RUBIN PAUL DChief Medical OfficerJan 02 '26Option Exercise4.7714,86670,94016,303Jan 06 12:00 AM
RUBIN PAUL DChief Medical OfficerJan 02 '26Sale12.857,43395,4900Jan 06 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR